A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma
Latest Information Update: 12 Jun 2025
At a glance
- Drugs PDS 0101 (Primary) ; PDS 0301 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms VERSATILE-003
- Sponsors PDS Biotechnology Corporation
Most Recent Events
- 09 Jun 2025 According to a PDS Biotechnology Corporation Media Release, Dr Price is the global principal investigator for the VERSATILE-003 study
- 22 May 2025 Trial design presented in the Media Release
- 21 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 May 2025.